TherapeuticsMD (NASDAQ:TXMD) has been given a $9.00 price target by equities researchers at Deutsche Bank in a note issued to investors on Wednesday, December 20th. The brokerage currently has a “buy” rating on the stock. Deutsche Bank’s target price points to a potential upside of 46.34% from the stock’s current price.
Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Oppenheimer set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a research note on Monday, October 16th. Jefferies Group reissued a “buy” rating and set a $15.00 target price on shares of TherapeuticsMD in a research note on Tuesday, September 26th. BidaskClub raised shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Friday, September 8th. Finally, Noble Financial reaffirmed a “buy” rating on shares of TherapeuticsMD in a research note on Thursday, November 30th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $14.50.
TherapeuticsMD (NASDAQ TXMD) traded down $0.09 on Wednesday, hitting $6.15. 1,300,000 shares of the stock traded hands, compared to its average volume of 2,680,000. TherapeuticsMD has a 52 week low of $3.50 and a 52 week high of $8.30. The firm has a market capitalization of $1,330.00, a PE ratio of -15.77 and a beta of 1.06.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. The company had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. TherapeuticsMD’s revenue for the quarter was down 19.7% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.13) earnings per share. equities research analysts expect that TherapeuticsMD will post -0.37 EPS for the current fiscal year.
In related news, Director Tommy G. Thompson acquired 5,000 shares of the firm’s stock in a transaction that occurred on Friday, December 8th. The stock was acquired at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the acquisition, the director now owns 3,555 shares of the company’s stock, valued at approximately $22,076.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 23.92% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of TXMD. Amalgamated Bank increased its stake in shares of TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in shares of TherapeuticsMD in the second quarter worth about $157,000. Quantbot Technologies LP purchased a new position in shares of TherapeuticsMD in the third quarter worth about $189,000. Finally, Cetera Investment Advisers purchased a new position in shares of TherapeuticsMD in the second quarter worth about $214,000. Institutional investors and hedge funds own 73.69% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “TherapeuticsMD (NASDAQ:TXMD) PT Set at $9.00 by Deutsche Bank” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://ledgergazette.com/2018/01/13/therapeuticsmd-txmd-given-a-9-00-price-target-by-deutsche-bank-analysts.html.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.